Synthesis and antimicrobial activity evaluation of pyrazole derivatives containing the imidazo[2,1-b][1,3,4]thiadiazole moiety
- PMID: 37328442
- DOI: 10.1002/ardp.202300110
Synthesis and antimicrobial activity evaluation of pyrazole derivatives containing the imidazo[2,1-b][1,3,4]thiadiazole moiety
Abstract
Four series of novel pyrazole derivatives (compounds 17a-m, 18a-m, 19a-g, and 20a-g) were synthesized, and their antibacterial and antifungal activities were evaluated. Most of the target compounds (17a-m, 18k-m, and 19b-g) showed strong antifungal activity and high selectivity relative to both Gram-positive and Gram-negative bacteria. Among them, compounds 17l (minimum inhibitory concentration [MIC] = 0.25 µg/mL) and 17m (MIC = 0.25 µg/mL) showed the strongest antifungal activity, being 2- and 4-fold more active than the positive controls gatifloxacin and fluconazole, respectively. In particular, compound 17l showed little cytotoxicity against human LO2 cells and did not exhibit hemolysis at ultrahigh concentrations, as did the positive control compounds gatifloxacin and fluconazole. These results indicate that these compounds are valuable for further development as antifungal agents.
Keywords: antibacterial; antifungal; hemolysis; pyrazole; thiadiazole.
© 2023 Deutsche Pharmazeutische Gesellschaft.
References
REFERENCES
-
- M. C. Fisher, D. A. Henk, C. J. Briggs, J. S. Brownstein, L. C. Madoff, S. L. McCraw, S. J. Gurr, Nature 2012, 484, 186.
-
- S. V. Lynch, O. Pedersen, N. Engl. J. Med 2016, 375, 2369.
-
- D. C. Angus, T. van der Poll, N. Engl. J. Med. 2013, 369, 840.
-
- G. D. Brown, D. W. Denning, N. A. R. Gow, S. M. Levitz, M. G. Netea, T. C. White, Sci. Transl. Med. 2012, 4, 165rv13.
-
- S. Cascioferro, B. Parrino, D. Carbone, C. Pecoraro, P. Diana, Future Med. Chem. 2021, 13, 529.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
